The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer

Cell Proliferation

Volumn 36, Issue 3, 2003, Pages 131-149

  Vermeulen, Katrien ^a   Van Bockstaele, Dirk R ^a   Berneman, Zwi N ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 BIS(2 HYDROXYETHYL)AMINO 9 ISOPROPYL 6 (4 METHOXYBENZYLAMINO)PURINE; 2,6 DIAMINO 4 CYCLOHEXYLMETHOXY 5 NITROSOPYRIMIDINE; 5 CHLOROINDIRUBIN; 6 N (3,3 DIMETHYLALLYL)ADENINE; 6 O CYCLOHEXYLMETHYLGUANINE; 7 HYDROXYSTAUROSPORINE; ALSTERPAULLONE; BUTYROLACTONE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; CYTOKININ; DIMETHYLAMINOPURINE; FLAVONOID; FLAVOPIRIDOL; GENISTEIN; GUANINE DERIVATIVE; INDIRUBIN; INDOLE DERIVATIVE; KENPAULLONE; MITOXANTRONE; OLOMOUCINE; OXOFLAVOPIRIDOL; PAULLONE DERIVATIVE; PURINE DERIVATIVE; PURVALANOL A; PURVALANOL B; PYRIMIDINE DERIVATIVE; QUERCETIN; ROSCOVITINE; SU 9516; THIOFLAVOPIRIDOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER CELL; CARCINOGENESIS; CARCINOMA; CELL CYCLE; CELL DIVISION; CELL MATURATION; CELL PROLIFERATION; CLINICAL TRIAL; DNA DAMAGE; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; HUMAN; NONHUMAN; REGULATORY MECHANISM; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASES; CYCLINS; DRUG DESIGN; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; PHOSPHORYLATION;

EID: 0038052805     PISSN: 09607722     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2184.2003.00266.x     Document Type: Review

References (177)

1. ABRAHAM RT, ACQUARONE M, ANDERSEN A, ASENSI A, BELLE R, BERGER F, BERGOUNIOUX C, BRUNN G, BUQUET FC, FAGOT D, GLAB N, GOUDEAU H, GOUDEAU M, GUERRIER P, HOUGHTON P, HENDRIKS H, KLOAREG B, LIPPAI M, MARIE D, MARO B, MEIJER L, MESTER J, MULNER-LORILLON O, POULET S, SCHIERENBERG E, SCHUTTE B, VAULOT D, VERLHAC M (1995) Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol. Cell 83, 105.
2. AGARWAL ML, TAYLOR WR, CHERNOV MV, CHERNOVA OB, STARK GR (1998) The p53 network. J. Biol. Chem. 273, 1.
3. AMON A (1999) The spindle checkpoint. Curr. Opin. Genet. Dev. 9, 69.
4. ANDREANI A, GRANAIOLA M, LEONI A, LOCATELLI A, MORIGI R, RAMBALDI M, GIORGI G, SALVINI L, GARALIENE V (2001) Synthesis and antitumor activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones. Anticancer Drug Des. 16, 167.
5. ARELLANO M, MORENO S (1997) Regulation of CDK/cyclin complexes during the cell cycle. Int. J. Biochem. Cell Biol. 29, 559.
6. ARRIS CE, BOYLE FT, CALVERT AH, CURTIN NJ, ENDICOTT JA, GARMAN EF, GIBSON AE, GOLDING BT, GRANT S, GRIFFIN RJ, JEWSBURY P, JOHNSON LN, LAWRIE AM, NEWELL DR, NOBLE MEM, SAUSVILLE EA, SCHULTZ R, YU W (2000) Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J. Med. Chem. 43, 2797.
7. ASSOIAN RK, ZHU X (1997) Cell anchorage and the cytoskeleton as partners in growth factor dependent cell cycle progression. Curr. Opin. Cell Biol. 9, 93.
8. BARTEK J, BARTKOVA J, LUKAS J (1996) The retinoblastoma protein pathway and the restriction point. Curr. Opin. Cell Biol. 8, 805.
9. BARVIAN M, BOSCHELLI DH, COSSROW J, DOBRUSIN E, FATTAEY A, FRITSCH A, FRY D, HARVEY P, KELLER P, GARRETT M, LA F, LEOPOLD W, MCNAMARA D, QUIN M, TRUMPP-KALLMEYER S, TOOGOOD P, WU Z, ZHANG E (2000) Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J. Med. Chem. 43, 4606.
10. BATES S, PARRY D, BONETTA L, VOUSDEN K, DICKSON C, PETERS G (1994) Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. Oncogene 9, 1633.
11. BLANGY A, LANE HA, D'HERIN P, HARPER M, KRESS M, NIGG EA (1995) Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 83, 1159.
12. BOJANOWSKI K, NISHIO K, FUKUDA M, LARSEN AK, SAIJO N (1994) Effect of suramin on p34cdc2 kinase in vitro and in extracts from human H69 cells: evidence for a double mechanism of action. Biochem. Biophys. Res. Commun. 203, 1574.
13. BRADBURY EM, INGLIS RJ, MATTHEWS HR (1974) Control of cell division by very lysine rich histone (F1) phosphorylation. Nature 247, 257.
14. BRAMSON HN, CORONA J, DAVIS ST, DICKERSON SH, EDELSTEIN M, FRYE SV, GAMPE R-TJ, HARRIS PA, HASSELL A, HOLMES WD, HUNTER RN, LACKEY KE, LOVEJOY B, LUZZIO MJ, MONTANA V, ROCQUE WJ, RUSNAK D, SHEWCHUK L, VEAL JM, WALKER DH, KUYPER LF (2001) Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis. J. Med. Chem. 44, 4339.
15. BREHM A, MISKA EA, MCCANCE DJ, REID JL, BANNISTER AJ, KOUZARIDES T (1998) Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391, 597.
16. BROOKS EE, GRAY NS, JOLY A, KERWAR SS, LUM R, MACKMAN RL, NORMAN TC, ROSETE J, ROWE M, SCHOW SR, SCHULTZ PG, WANG X, WICK MM, SHIFFMAN D (1997) CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J. Biol. Chem. 272, 29207.
17. BUCHKOVICH K, DUFFY LA, HARLOW E (1989) The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58, 1097.
18. BUESO-RAMOS CE, MANSHOURI T, HAIDAR MA, HUH YO, KEATING MJ, ALBITAR M (1995) Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis. Leuk. Lymphoma 17, 13.
19. BUESO-RAMOS CE, MANSHOURI T, HAIDAR MA, YANG Y, MCCOWN P, ORDONEZ N, GLASSMAN A, SNEIGE N, ALBITAR M (1996) Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res. Treat. 37, 179.
20. BURMA S, KURIMASA A, XIE G, TAYA Y, ARAKI R, ABE M, CRISSMAN HA, OUYANG H, LI GC, CHEN DJ (1999) DNA-dependent protein kinase-independent activation of p53 in response to DNA damage. J. Biol. Chem. 274, 17139.
21. CARLSON BA, DUBAY MM, SAUSVILLE EA, BRIZUELA L, WORLAND PJ (1996) Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 56, 2973.
22. CARNERO A, HANNON GJ (1998) The INK4 family of CDK inhibitors. Curr. Top. Microbiol. Immunol. 227, 43.
23. CHANG YT, GRAY NS, ROSANIA GR, SUTHERLIN DP, KWON S, NORMAN TC, SAROHIA R, LEOST M, MEIJER L, SCHULTZ PG (1999) Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem. Biol. 6, 361.
24. CLOUGH J (2002) CDK inhibitor shows promise for inflammatory kidney disease. Drug Discovery Today 7, 789.
25. COURVALIN JC, SEGIL N, BLOBEL G, WORMAN HJ (1992) The lamin B receptor of the inner nuclear membrane undergoes mitosis-specific phosphorylation and is a substrate for p34cdc2-type protein kinase. J. Biol. Chem. 267, 19035.
26. CROOK T, VOUSDEN KH (1994) Interaction of HPV E6 with p53 and associated proteins. Biochem. Soc. Trans. 22, 52.
27. DAVIS ST, BENSON BG, BRAMSON HN, CHAPMAN DE, DICKERSON SH, DOLD KM, EBERWEIN DJ, EDELSTEIN M, FRYE SV, GAMPE RT, JRGRIFFIN RJ, HARRIS PA, HASSELL AM, HOLMES WD, HUNTER RN, KNICK VB, LACKEY K, LOVEJOY B, LUZZIO MJ, MURRAY D, PARKER P, ROCQUE WJ, SHEWCHUK L, VEAL JM, WALKER DH, KUYPER LF (2001) Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science 291, 134.
28. DAVIES TG, BENTLEY J, ARRIS CE, BOYLE FT, CURTIN NJ, ENDICOTT JA, GIBSON AE, GOLDING BT, GRIFFIN RJ, HARDCASTLE IR, JEWSBURY P, JOHNSON LN, MESGUICHE V, NEWELL DR, NOBLE MEM, TUCKER JA, WANG L, WHITFIELD HJ (2002) Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat. Struct. Biol. 9, 745.
29. DE AZEVEDO WF, LECLERC S, MEIJER L, HAVLICEK L, STRNAD M, KIM SH (1997) Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human CDK2 complexed with roscovitine. Eur. J. Biochem. 243, 518.
30. EL DEIRY WS, TOKINO T, VELCULESCU VE, LEVY DB, PARSONS R, TRENT JM, LIN D, MERCER WE, KINZLER KW, VOGELSTEIN B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817.
31. DENG C, ZHANG P, HARPER JW, ELLEDGE SJ, LEDER P (1995) Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82, 675.
32. DOBASHI Y, SHOJI M, JIANG SX, KOBAYASHI M, KAWAKUBO Y, KAMEYA T (1998) Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am. J. Pathol. 153, 963.
33. DREES M, DENGLER WA, ROTH T, LABONTE H, MAYO J, MALSPEIS L, GREVER M, SAUSVILLE EA, FIEBIG HH (1997) Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin. Cancer Res. 3, 273.
34. DREYER MK, BORCHERDING DR, DUMONT JA, PEET NP, TSAY JT, WRIGHT PS, BITONTI AJ, SHEN J, KIM SH (2001) Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717. J. Med. Chem. 44, 524.
35. DUROCHER D, JACKSON SP (2001) DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr. Opin. Cell Biol. 13, 225.
36. EASTON J, WEI T, LAHTI JM, KIDD VJ (1998) Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma. Cancer Res. 58, 2624-2632.
37. ESPOSITO V, BALDI A, DE LUCA A, GROGER AM, LODA M, GIORDANO GG, CAPUTI M, BALDI F, PAGANO M, GIORDANO A (1997) Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 57, 3381.
38. EVANS T, ROSENTHAL ET, YOUNGBLOM J, DISTEL D, HUNT T (1983) Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell 33, 389.
39. FANG G, YU H, KIRSCHNER MW (1998) The checkpoint protein MAD2 and the mitotic regulator CDC20 form a ternary complex with the anaphase-promoting complex to control anaphase initiation. Genes Dev. 12, 1871.
40. FISHER RP, MORGAN DO (1994) A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell 78, 713.
41. GADBOIS DM, HAMAGUCHI JR, SWANK RA, BRADBURY EM (1992) Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases. Biochem. Biophys. Res. Commun. 184, 80.
42. GAGE JR, MEYERS C, WETTSTEIN FO (1990) The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties. J. Virol. 64, 723.
43. GALAKTIONOV K, JESSUS C, BEACH D (1995) Rafl interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation. Genes Dev. 9, 1046.
44. GALAKTIONOV K, CHEN X, BEACH D (1996) Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 382, 511.
45. GIBSON AE, ARRIS CE, BENTLEY J, BOYLE FT, CURTIN NJ, DAVIES TG, ENDICOTT JA, GOLDING BT, GRANT S, GRIFFIN RJ, JEWSBURY P, JOHNSON LN, MESGUICHE V, NEWELL DR, NOBLE MEM, TUCKER JA, WHITFIELD HJ (2002) Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J. Med. Chem. 45, 3381.
46. GIRARD F, STRAUSFELD U, FERNANDEZ A, LAMB NJ (1991) Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 67, 1169.
47. GLOTZER M, MURRAY AW, KIRSCHNER MW (1991) Cyclin is degraded by the ubiquitin pathway [see comments]. Nature 349, 132.
48. GOTTLIEB TM, OREN M (1998) p53 and apoptosis. Semin. Cancer Biol. 8, 359.
49. GRAY NS, WODICKA L, THUNNISSEN AM, NORMAN TC, KWON S, ESPINOZA FH, MORGAN DO, BARNES G, LECLERC S, MEIJER L, KIM SH, LOCKHART DJ, SCHULTZ PG (1998) Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281, 533.
50. GREENBLATT MS, BENNETT WP, HOLLSTEIN M, HARRIS CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855.
51. GRONBAEK K, NEDERGAARD T, ANDERSEN MK, THOR SP, GULDBERG P, MOLLER P, ZEUTHEN J, EBBE HN, HOU JK, RALFKIAER E (1998) Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, 16, 15, 53 and pRb. Leukemia 12, 1266.
52. HAJDUCH M, KOLAR Z, NOVOTNY R, HANUS J, MIHAL V, HLOBILKOVA A, NOSKOVA V, STRNAD M (1997) Induction of apoptosis and regression of spontaneous dog melanoma following in vivo application of synthetic cyclin-dependent kinase inhibitor olomoucine. Anticancer Drugs 8, 1007.
53. HALL M, PETERS G (1996) Genetic alterations of cyclins, cyclin-dependent kinases, and CDK inhibitors in human cancer. Adv. Cancer Res. 68, 67.
54. HANNON GJ, BEACH D (1994) p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371, 257.
55. HARPER JW, ELLEDGE SJ, KEYOMARSI K, DYNLACHT B, TSAI LH, ZHANG P, DOBROWOLSKI S, BAI C, CONNELL CL, SWINDELL E, et al. (1995) Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell 6, 387.
56. HARPER JW, ELLEDGE SJ (1996) Cdk inhibitors in development and cancer. Curr. Opin. Genet. Dev. 6, 56.
57. HARTWELL LH, WEINERT TA (1989) Checkpoints: controls that ensure the order of cell cycle events. Science 246, 629.
58. HEALD R, MCKEON F (1990) Mutations of phosphorylation sites in lamin A that prevent nuclear lamina disassembly in mitosis. Cell 61, 579.
59. HEALD R, MCLOUGHLIN M, MCKEON F (1993) Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase. Cell 74, 463.
60. HENGST L, REED SI (1998) Inhibitors of the Cip/Kip family. Curr. Top. Microbiol. Immunol. 227, 25.
61. HERMEKING H, LENGAUER C, POLYAK K, HE TC, ZHANG L, THIAGALINGAM S, KINZLER KW, VOGELSTEIN B (1997) 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol. Cell 1, 3.
62. VAN DEN HEUVEL SJ, VAN LAAR T, KAST WM, MELIEF CJ, ZANTEMA A, VAN DER EB AJ (1990) Association between the cellular p53 and the adenovirus 5 E1B-55kd proteins reduces the oncogenicity of Ad-transformed cells. EMBO J. 9, 2621.
63. HINDS PW, MITTNACHT S, DULIC V, ARNOLD A, REED SI, WEINBERG RA (1992) Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70, 993.
64. HOESSEL R, LECLERC S, ENDICOTT JA, NOBEL ME, LAWRIE A, TUNNAH P, LEOST M, DAMIENS E, MARIE D, MARKO D, NIEDERBERGER E, TANG W, EISENBRAND G, MEIJER L (1999) Indirubin, the active constituent of a Chinese anti-leukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1, 60.
65. HOFFMANN I, CLARKE PR, MARCOTE MJ, KARSENTI E, DRAETTA G (1993) Phosphorylation and activation of human cdc25-C by cdc2 - cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO J. 12, 53.
66. HORSTHEMKE B (1992) Genetics and cytogenetics of retinoblastoma. Cancer Genet. Cytogenet. 63, 1.
67. HU QJ, DYSON N, HARLOW E (1990) The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations. EMBO J. 9, 1147.
68. HUNTER T, PINES J (1994) Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79, 573.
69. IIDA H, TOWATARI M, TANIMOTO M, MORISHITA Y, KODERA Y, SAITO H (1997) Overexpression of cyclin E in acute myelogenous leukemia. Blood 90, 3707.
70. JEFFREY PD, RUSSO AA, POLYAK K, GIBBS E, HURWITZ J, MASSAGUE J, PAVLETICH NP (1995) Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376, 313.
71. JIANG W, ZHANG YJ, KAHN SM, HOLLSTEIN MC, SANTELLA RM, LU SH, HARRIS CC, MONTESANO R, WEINSTEIN IB (1993) Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc. Natl Acad. Sci. USA 90, 9026.
72. KAMB A (1998) Cyclin-dependent kinase inhibitors and human cancer. Curr. Top. Microbiol. Immunol. 227, 139.
73. KATO J, MATSUSHIME H, HIEBERT SW, EWEN ME, SHERR CJ (1993) Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. 7, 331.
74. KAUR G, STETLER SM, SEBERS S, WORLAND P, SEDLACEK H, MYERS C, CZECH J, NAIK R, SAUSVILLE E (1992) Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl Cancer Inst. 84, 1736.
75. KAWAKAMI K, FUTAMI H, TAKAHARA J, YAMAGUCHI K (1996) UCN-1,7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem. Biophys. Res. Commun. 219, 778.
76. KEYOMARSI K, CONTE D, TOYOFUKU W, FOX MP (1995) Deregulation of cyclin E in breast cancer. Oncogene 11, 941.
77. KIM JH, KANG MJ, PARK CU, KWAK HJ, HWANG Y, KOH GY (1999) Amplified CDK2 and cdc2 activities in primary colorectal carcinoma. Cancer 85, 546.
78. KIM KS, SACK JS, TOKARSKI JS, QIAN L, CHAO ST, LEITH L, KELLY YF, MISRA RN, HUNT JT, KIMBALL SD, HUMPHREYS WG, WAUTLET BS, MULHERON JG, WEBSTER KR (2000) Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. J. Med. Chem. 43, 4126.
79. KIM KS, KIMBALL SD, MISRA RN, RAWLINS DB, HUNT JT, XIAO HY, LU S, QIAN L, HAN WC, SHAN W, MITT T, CAI ZW, POSS MA, ZHU H, SACK JS, TOKARSKI JS, CHANG CY, PAVLETICH N, KAMATH A, HUMPHREYS WG, MARATHE P, BURSUKER I, KELLAR KA, ROONGTA U, BATORSKY R., MULHERON JG, BOL D, FAIRCHILD CR, LEE FY, WEBSTER KR (2002) Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities. J. Med. Chem. 45, 3905.
80. KING RW, JACKSON PK, KIRSCHNER MW (1994) Mitosis in transition. Cell 79, 563.
81. KING RW, DESHAIES RJ, PETERS JM, KIRSCHNER MW (1996) How proteolysis drives the cell cycle. Science 274, 1652.
82. KITAGAWA M, OKABE T, OGINO H, MATSUMOTO H, SUZUKI TI, KOKUBO T, HIGASHI H, SAITOH S, TAYA Y, YASUDA H et al. (1993) Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. Oncogene 8, 2425-2432.
83. KITAGAWA M, HIGASHI H, TAKAHASHI IS, OKABE T, OGINO H, TAYA Y, HISHIMURA S, OKUYAMA A (1994) A cyclin-dependent kinase inhibitor, butyrolactone 1, inhibits phosphorylation of RB protein and cell cycle progression. Oncogene 9, 2549.
84. KNUDSON AGJ (1971) Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68, 820.
85. KO LJ, PRIVES C (1996) p53: puzzle and paradigm. Genes Dev. 10, 1054.
86. KRYSTOF V, LENOBEL R, HAVLICEK L, KUZMA M, STRNAD M (2002) Synthesis and biological activity of olomoucine II. Bioorg. Med. Chem. Lett. 12, 3283.
87. LANE MEYUB, RICE A, LIPSON KE, LIANG C, SUN L, TANG C, MCMAHON G, PESTELL RG, WADLER S (2001) A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res. 61, 6170.
88. LAPOINTE J, LACHANCE Y, LABRIE Y, LABRIE C (1996) A p18 mutant defective in CDK6 binding in human breast cancer cells. Cancer Res. 56, 4586-4589.
89. LARSEN AK (1993) Suramin: an anticancer drug with unique biological effects. Cancer Chemother. Pharmacol. 32, 96.
90. LEACH FS, ELLEDGE SJ, SHERR CJ, WILLSON JK, MARKOWITZ S, KINZLER KW, VOGELSTEIN B (1993) Amplification of cyclin genes in colorectal carcinomas. Cancer Res. 53, 1986.
91. LEE MH, REYNISDOTTIR I, MASSAGUE J (1995) Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 9, 639.
92. LEGRAVEREND M, LUDWIG O, BISAGNI E, LECLERC S, MEIJER L, GIOCANTI N, SADRI R, FAVAUDON V (1999) Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors. Bioorg. Med. Chem. 7, 1281.
93. LEGRAVEREND M, TUNNAH P, NOBLE M, DUCROT P, LUDWIG O, GRIERSON DS, LEOST M, MEIJER L, ENDICOTT J (2000) Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex. J. Med. Chem. 43, 1282.
94. LEVINE AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88, 323.
95. LEW DJ, KORNBLUTH S (1996) Regulatory roles of cyclin-dependent kinase phosphorylation in cell cycle control. Curr. Opin. Cell Biol. 8, 795.
96. LIM DS, KIM ST, XU B, MASER RS, LIN J, PETRINI JH, KASTAN MB (2000) ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature 404, 613.
97. LIU F, STANTON JJ, WU Z, PIWNICA WH (1997) The human Mytl kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex. Mol. Cell Biol. 17, 571.
98. LODA M, CUKOR B, TAM SW, LAVIN P, FIORENTINO M, DRAETTA GF, JESSUP JM, PAGANO M (1997) Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 3, 231.
99. LOSIEWICZ MD, CARLSON BA, KAUR G, SAUSVILLE EA, WORLAND PJ (1994) Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun. 201, 589.
100. LOWE SW, BODIS S, MCCLATCHEY A, REMINGTON L, RULEY HE, FISHER DE, HOUSMAN DE, JACKS T (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266, 807.
101. MAIK RG, KATTICE SL, BHAT SV (1988) An anti-inflammatory cum immodulatory piperidinylbenzopyranone from Dysoxylum binectariferum: isolation, structure, and total synthesis. Tetrahedron 44, 2081.
102. MARKO D, SCHATZLE S, FRIEDEL A, GENZLINGER A, ZANKL H, MEIJER L, EISENBRAND G (2001) Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br. J. Cancer 84, 283.
103. MCDONALD ER III, EL DEIRY WS (2000) Cell cycle control as a basis for cancer drug development. Int. J. Oncol. 16, 871.
104. MEIJER L, PONDAVEN P (1988) Cyclic activation of histone H1 kinase during sea urchin egg mitotic divisions. Exp. Cell Res. 174, 116-129.
105. MEIJER L, BORGNE A, MULNER O, CHONG JP, BLOW JJ, INAGAKI N, INAGAKI M, DELCROS JG, MOULINOUX JP (1997) Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243, 527.
106. MEIJER L, THUNNISSEN AM, WHITE AW, GARNIER M, NIKOLIC M, TSAI LH, WALTER J, CLEVERLEY KE, SALINAS PC, WU YZ, BIERNAT J, MANDELKOW EM, KIM SH, PETTIT GR (2000) Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 7, 51.
107. MILLER C, KOEFFLER HP (1993) P53 mutations in human cancer. Leukemia 7, S18.
108. MOLLER MB, INO Y, GERDES A, SKJOOT K, LOUIS D, PEDERSEN N (1999) Aberration of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. Leukemia 13, 453.
109. MONTAGNOLI A, FIORE F, EYTAN E, CARRANO AC, DRAETTA GF, HERSHKO A, PAGANO M (1999) Ubiquitination of p27 is regulated by CDK-dependent phosphorylation and trimeric complex formation. Genes Dev. 13, 1181.
110. MORGAN DO (1995) Principles of CDK regulation. Nature 374, 131.
111. MOTOKURA T, BLOOM T, KIM HG, JUPPNER H, RUDERMAN JV, KRONENBERG HM, ARNOLD A (1991) A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 350, 512.
112. NATARAJ AJ, TRENT JC, ANANTHASWAMY HN (1995) p53 gene mutations and photocarcinogenesis. Photochem. Photobiol. 62, 218.
113. NEANT I, GUERRIER P (1988) 6-Dimethylaminopurine blocks starfish oocyte maturation by inhibiting a relevant protein kinase activity. Exp. Cell Res. 176, 68.
114. NILSSON I, HOFFMANN I (2000) Cell cycle regulation by the Cdc25 phosphatase family. Prog. Cell Cycle Res. 4, 107.
115. NISHIO K, ISHIDA T, ARIOKA H, KUROKAWA H, FUKUOKA K, NOMOTO T, FUKUMOTO H, YOKOTE H, SAIJO N (1996) Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines. Anticancer Res. 16, 3387.
116. NORBURY C, NURSE P (1992) Animal cell cycles and their control. Annu. Rev. Biochem. 61, 441.
117. OHASHI M, SUGIKAWA E, NAKANISHI N (1995) Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism. Jpn. J. Cancer Res. 86, 819.
118. OHTSUBO M, THEODORAS AM, SCHUMACHER J, ROBERTS JM, PAGANO M (1995) Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol. Cell Biol. 15, 2612.
119. OKAMOTO K, BEACH D (1994) Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J. 13, 4816-4822.
120. OKAMOTO A, DEMETRICK DJ, SPILLARE EA, HAGIWARA K, HUSSAIN SP, BENNETT WP, FORRESTER K, GERWIN B, SERRANO M, BEACH DH (1994) Mutations and altered expression of p16INK4 in human cancer. Proc. Natl Acad. Sci. USA 91, 11045.
121. ONGKEKO W, FERGUSON DJ, HARRIS AL, NORBURY C (1995) Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage. J. Cell Sci. 108, 2897.
122. OREN M (1999) Regulation of the p53 tumor suppressor protein. J. Biol. Chem. 274, 36031.
123. OWEN-SCHAUB LB, ZHANG W, CUSACK JC, ANGELO LS, SANTEE SM, FUJIWARA T, ROTH JA, DEISSEROTH AB, ZHANG WW, KRUZEL EA (1995) Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell Biol. 15, 3032.
124. PAGANO M (1997) Cell cycle regulation by the ubiquitin pathway. FASEB J. 11, 1067.
125. PAINTER RB (1986) Inhibition of mammalian cell DNA synthesis by ionizing radiation. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 49, 771.
126. PAN ZQ, REARDON JT, LI L, FLORES RH, LEGERSKI R, SANCAR A, HURWITZ J (1995) Inhibition of nucleotide excision repair by the cyclin-dependent kinase inhibitor p21. J. Biol. Chem. 270, 22008.
127. PARDEE AB (1974) A restriction point for control of normal animal cell proliferation. Proc. Natl Acad. Sci. USA 71, 1286.
128. PARK SG, CHEON JY, LEE YH, PARK JS, LEE KY, LEE CH, LEE SK (1996) A specific inhibitor of cyclin-dependent protein kinases, CDC2 and CDK2. Mol. Cell 6, 679.
129. PARKER BW, KAUR G, NIEVES NW, TAIMI M, KOHLHAGEN G, SHIMIZU T, LOSIEWICZ MD, POMMIER Y, SAUSVILLE EA, SENDEROWICZ AM (1998) Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 91, 458.
130. PARRY D, BATES S, MANN DJ, PETERS G (1995) Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J. 14, 503.
131. PAULOVICH AG, HARTWELL LH (1995) A checkpoint regulates the rate of progression through S phase in S. cerevisiae in response to DNA damage. Cell 82, 841.
132. PENG CY, GRAVES PR, THOMA RS, WU Z, SHAW AS, PIWNICA WH (1997) Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216 [see comments]. Science 277, 1501.
133. PENG J, MARSHALL NF, PRICE DH (1998) Identification of a cyclin subunit required for the function of Drosophila P-TEFb. J. Biol. Chem. 273, 13855.
134. PINES J (1991) Cyclins: wheels within wheels. Cell Growth Differ. 2, 305.
135. PINES J (1995) Cyclins and cyclin-dependent kinases: theme and variations. Adv. Cancer Res. 66, 181.
136. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78, 59.
137. POLYAK K, XIA Y, ZWEIER JL, KINZLER KW, VOGELSTEIN B (1997) A model for p53-induced apoptosis. Nature 389, 300.
138. RECHSTEINER M, ROGERS SW (1996) PEST sequences and regulation by proteolysis. Trends Biochem. Sci. 21, 267.
139. REYNISDOTTIR I, POLYAK K, IAVARONE MASSAGUE J (1995) Kip/cip and INK4 CDK inhibitors co-operate to induce cell cycle arrest in respons to TGF-β. Genes Dev. 9, 1831.
140. RIALET V, MEIJER L (1991) A new screening test for antimitotic compounds using the universal M phase-specific protein kinase, p34cdc2/cyclin Bcdc13, affinity-immobilized on p13suc1-coated microtitration plates. Anticancer Res. 11, 1581.
141. RICKERT P, SEGHEZZI W, SHANAHAN F, CHO H, LEES E (1996) Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II. Oncogene 12, 2631.
142. SANCHEZ Y, WONG C, THOMA RS, RICHMAN R, WU Z, PIWNICA WH, ELLEDGE SJ (1997) Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277, 1497.
143. SCHULTZ C, LINK A, LEOST M, ZAHAREVITZ DW, GUSSIO R, SAUSVILLE EA, MEIJER L, KUNICK C (1999) Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J. Med. Chem. 42, 2909.
144. SCHULZE-GAHMEN U, BRANDSEN J, JONES HD, MORGAN DO, MEIJER L, VESELY J, KIM SH (1995) Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins 22, 378.
145. SCHUTTE B, NIELAND L, VAN ENGELAND M, HENFLING ME, MEIJER L, RAMAEKERS FC (1997) The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. Exp. Cell Res. 236, 4.
146. SCUDERI R, PALUCKA KA, POKROVSKAJA K, BJORKHOLM M, WIMAN KG, PISA P (1996) Cyclin E overexpression in relapsed adult acute lymphoblastic leukemias of B-cell lineage. Blood 87, 3360.
147. SENDEROWICZ A (2001) Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia 15, 1.
148. SENDEROWICZ AM, SAUSVILLE EA (2000) Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl Cancer Inst 92, 376.
149. SHERR CJ (1994) G1 phase progression: cycling on cue. Cell 79, 551.
150. SHERR CJ (1996) Cancer cell cycles. Science 274, 1672.
151. SHERR CJ, ROBERTS JM (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9, 1149.
152. SHEWCHUK L, HASSELL A, WISELY B, ROCQUE W, HOLMES W, VEAL J, KUYPER LF (2000) Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J. Med. Chem. 43, 133.
153. SHI Y, ZOU M, FARID NR, AL SEDAIRY ST (1996) Evidence of gene deletion of p21 (WAF1/CIPI), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas. Br. J. Cancer 74, 1336.
154. SIELECKI TM, JOHNSON TL, LIU J, MUCKELBAUER JK, GRAFSTROM RH, COX S, BOYLAN J, BURTON CR, CHEN H, SMALLWOOD A, CHANG CH, BOISCLAIR M, BENFIELD PA, TRAINOR GL, SEITZ SP (2001) Quinazolines as cyclin dependent kinase inhibitors. Bioorg. Med. Chem. Lett. 11, 1157.
155. SILICIANO JD, CANMAN CE, TAYA Y, SAKAGUCHI K, APPELLA E, KASTAN MB (1997) DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 11, 3471.
156. TAKAHASHI I, SAITOH Y, YOSHIDA M, SANO H, NAKANO H, MORIMOTO M, TAMAOKI T (1989) UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities. J. Antibiot. Tokyo 42, 571.
157. TAMAOKI T (1991) Use and specificity of staurosporine, UCN-01, and calphostin C as protein kinase inhibitors. Meth. Enzymol. 201, 340.
158. TAN P, CADY B, WANNER M, WORLAND P, CUKOR B, MAGI GC, LAVIN P, DRAETTA G, PAGANO M, LODA M (1997) The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res. 57, 1259.
159. TAYLOR WR, STARK GR (2001) Regulation of the G2/M transition by p53. Oncogene 20, 1803.
160. TSAI T, DAVALATH S, RANKIN C, RADICH JP, HEAD D, APPELBAUM FR, BOLDT DH (1996) Tumor suppressor gene alteration in adult acute lymphoblastic leukemia (ALL). Analysis of retinoblastoma (Rb) and p53 gene expression in lymphoblasts of patients with de novo, relapsed, or refractory ALL treated in Southwest Oncology Group studies. Leukemia 10, 1901.
161. VERMEULEN K, STRNAD M, KRYSTOF V, HAVLICEK L, VAN DER AA A, LENJOU M, NIJS G, RODRIGUS I, STOCKMAN B, VAN ONCKELEN H, VAN BOCKSTAELE D, BERNEMAN ZN (2002a) Antiproliferative effect on plant cytokinin analogues with an inhibitory activity on cyclin-dependent kinases. Leukemia 16, 299.
162. VERMEULEN K, STRNAD M, HAVLICEK L, VAN ONCKELEN H, LENJOU M, NIJS G, VAN BOCKSTAELE D, BERNEMAN ZN (2002b) Plant cytokinin analogues with inhibitory activity on cyclin dependent kinases (CDK) exert their antiproliferative effect through induction of apoptosis initiated by the mitochondrial pathway: determination by a multiparametric flow cytometric analysis. Exp. Hematol. 30, 1107.
163. VESELY J, HAVLICEK L, STRNAD M, BLOW JJ, DONELLA DA, PINNA L, LETHAM DS, KATO J, DETIVAUD L, LECLERC S, MEIJER L (1994) Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 224, 771.
164. VOITENLEITNER C, FANNING E, NASHEUER HP (1997) Phosphorylation of DNA polymerase alpha-primase by cyclin A-dependent kinases regulates initiation of DNA replication in vitro. Oncogene 14, 1611.
165. WADA M, HOSOTANI R, LEE JU, DOI R, KOSHIBA T, FUJIMOTO K, MIYAMOTO Y, TSUJI S, NAKAJIMA S, OKUYAMA A, IMAMURA M (1998) An exogenous cdk inhibitor, butyrolactone-I, induces apoptosis with increased Bax/Bcl-2 ratio in p53-mutated pancreatic cancer cells. Anticancer Res. 18, 2559.
166. WAGA S, LI R, STILLMAN B (1997) p53-induced p21 controls DNA replication. Leukemia 11, 321.
167. WALKER DH, MAULER JL (1991) Role for cyclin A in the dependence of mitosis on completion of DNA replication. Nature 354, 314.
168. WANG Q, WORLAND PJ, CLARK JL, CARLSON BA, SAUSVILLE EA (1995) Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin dependent kianses 1 and 2. Cell Growth Differ. 6, 927.
169. WEISENBURGER DD, SANGER WG, ARMITAGE JO, PURTILO DT (1987) Intermediate lymphocytic lymphoma: immunophenotypic and cytogenetic findings. Blood 69, 1617.
170. WOLFEL T, HAUER M, SCHNEIDER J, SERRANO M, WOLFEL C, KLEHMANN HE, DE PLAEN E, HANKELN T, MEYERZUM-BUSCHENFELDE KH, BEACH D (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281.
171. YAMAMOTO H, MONDEN T, MIYOSHI H, IZAWA H, IKEDA K, TSUJIE M, OHNISHI T, SEKIMOTO M, TOMITA N, MONDEN M (1998) Cdk2/cdc2 expression in colon carcinogenesis and effects of cdk2/cdc2 inhibitor in colon cancer cells. Int. J. Oncol. 13, 233.
172. YANG J, WINKLER K, YOSHIDA M, KORNBLUTH S (1999) Maintenance of G2 arrest in the Xenopus oocyte: a role for 14-3-3 mediated inhibition of Cdc25 nuclear import. EMBO J. 18, 2174.
173. ZAHAREVITZ DW, GUSSIO R, LEOST M, SENDEROWICZ AM, LAHUSEN T, KUNICK C,
174. ZENG Y, FORBES KC, WU Z, MORENO S, PIWNICA WH, ENOCH T (1998) Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chkl. Nature 395, 507.
175. ZHAI S, SENDEROWICZ AM, SAUSVILLE EA, FIGG WD (2002) Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann. Pharmacother. 36, 905.
176. ZHANG Y, XIONG Y, YARBROUGH WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92, 725.
177. ZHAO J, KENNEDY BK, LAWRENCE BD, BARBIE DA, MATERA AG, FLETCHER JA, HARLOT E (2000) NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. Genes Dev. 14, 2283.